Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response
- PMID: 19715572
- PMCID: PMC2745815
- DOI: 10.1186/ar2798
Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response
Abstract
Introduction: Bone marrow (BM) is an immunologically privileged site where activated autoantibody-producing B cells may survive for prolonged periods. We investigated the effect of rituximab (anti-CD20 mAb) in peripheral blood (PB) and BM B-cell and T-cell populations in active rheumatoid arthritis (RA) patients.
Methods: Active RA patients received rituximab (1,000 mg) on days 1 and 15. PB (n = 11) and BM (n = 8) aspirates were collected at baseline and at 3 months. We assessed B-cell and T-cell populations using triple-color flow cytometry.
Results: Rituximab therapy decreased PB (from a mean 2% to 0.9%, P = 0.022) but not BM (from 4.6% to 3.8%, P = 0.273) CD19+ B cells, associated with a significant reduction in the activated CD19+HLA-DR+ subset both in PB (from 55% to 19%, P = 0.007) and in BM (from 68% to 19%, P = 0.007). Response to rituximab was preceded by a significant decrease in PB and BM CD19+CD27+ memory B cells (P = 0.022). These effects were specific to rituximab since anti-TNF therapy did not reduce total or activated B cells. Rituximab therapy did not alter the number of activated CD4+HLA-DR+ and CD4+CD25+ T cells.
Conclusions: Rituximab therapy preferentially depletes activated CD19+HLA-DR+ B cells in the PB and BM of active RA patients. Clinical response to rituximab is associated with depletion of CD19+CD27+ memory B cells in PB and BM of RA patients.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2745815/bin/ar2798-1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2745815/bin/ar2798-2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2745815/bin/ar2798-3.gif)
Similar articles
-
Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis.Arthritis Res Ther. 2009;11(4):R123. doi: 10.1186/ar2789. Epub 2009 Aug 17. Arthritis Res Ther. 2009. PMID: 19686595 Free PMC article.
-
Rituximab treatment in rheumatoid arthritis: how does it work?Arthritis Res Ther. 2009;11(6):134. doi: 10.1186/ar2852. Epub 2009 Nov 24. Arthritis Res Ther. 2009. PMID: 20017888 Free PMC article.
-
Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy.Rheumatology (Oxford). 2007 Jan;46(1):29-36. doi: 10.1093/rheumatology/kel148. Epub 2006 May 30. Rheumatology (Oxford). 2007. PMID: 16735454
-
CD19: a promising B cell target for rheumatoid arthritis.Nat Rev Rheumatol. 2009 Oct;5(10):572-7. doi: 10.1038/nrrheum.2009.184. Nat Rev Rheumatol. 2009. PMID: 19798033 Review.
-
Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis.Expert Opin Pharmacother. 2006 Dec;7(18):2559-70. doi: 10.1517/14656566.7.18.2559. Expert Opin Pharmacother. 2006. PMID: 17150009 Review.
Cited by
-
Exploring the depths of IgG4: insights into autoimmunity and novel treatments.Front Immunol. 2024 Apr 18;15:1346671. doi: 10.3389/fimmu.2024.1346671. eCollection 2024. Front Immunol. 2024. PMID: 38698867 Free PMC article. Review.
-
Nonspecific Orbital Inflammation (NSOI): Unraveling the Molecular Pathogenesis, Diagnostic Modalities, and Therapeutic Interventions.Int J Mol Sci. 2024 Jan 26;25(3):1553. doi: 10.3390/ijms25031553. Int J Mol Sci. 2024. PMID: 38338832 Free PMC article. Review.
-
Current Insights Into K-associated Fetal Anemia and Potential Treatment Strategies for Sensitized Pregnancies.Transfus Med Rev. 2024 Jan;38(1):150779. doi: 10.1016/j.tmrv.2023.150779. Epub 2023 Oct 15. Transfus Med Rev. 2024. PMID: 37926651 Review.
-
Inflammation is responsible for systemic bone loss in patients with seropositive rheumatoid arthritis treated with rituximab.Korean J Intern Med. 2023 Nov;38(6):912-922. doi: 10.3904/kjim.2023.080. Epub 2023 Oct 23. Korean J Intern Med. 2023. PMID: 37867140 Free PMC article.
-
Obinutuzumab Effectively Depletes Key B-cell Subsets in Blood and Tissue in End-stage Renal Disease Patients.Transplant Direct. 2023 Jan 19;9(2):e1436. doi: 10.1097/TXD.0000000000001436. eCollection 2023 Feb. Transplant Direct. 2023. PMID: 36700064 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials